# Data Sheet (Cat.No.T1111)

TargetMol

## Pralidoxime Chloride

### Chemical Properties

CAS No. : 51-15-0

Formula: C7H9ClN2O

Molecular Weight: 172.61

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.




### Biological Description

| | |
|---|---|
| Description | Pralidoxime Chloride (2-PAM chloride) is a useful agent in the treatment of organophosphate poisoning. Pralidoxime binds to organophosphate-inactivated acetylcholinesterase, used to combat poisoning by organophosphates or acetylcholinesterase inhibitors (nerve agents). |
| Targets(IC50) | Cholinesterase (ChE) |
| In vitro | The application of pralidoxime allowed the regeneration of an important fraction of inhibited AChE, process which is concentration-dependent[1]. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 50 mg/mL (289.67 mM),Sonication and heating are recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (11.59 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 5.7934 mL | 28.967 mL | 57.9341 mL |
| 5 mM | 1.1587 mL | 5.7934 mL | 11.5868 mL |
| 10 mM | 0.5793 mL | 2.8967 mL | 5.7934 mL |
| 50 mM | 0.1159 mL | 0.5793 mL | 1.1587 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ríos JC, et al. Toxicol In Vitro. 2005 Oct;19(7):893-7. Epub 2005 Aug 19.
Zareifi D S, Chaliotis O, Chala N, et al. A Network-Based Computational and Experimental Framework for Repurposing Compounds Towards the Treatment of Non-Alcoholic Fatty Liver Disease. iScience. 2022: 103890.
Zareifi D S, Chaliotis O, Chala N, et al. A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease. Iscience. 2022, 25(3): 103890